Tokyo Tape
Sign in
← Immuno-Biological Laboratories

Quarterly report · Q3

4570.TEDINET S100Q59N
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥555m2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥648m2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥448m2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥19m2022-04-01 → 2022-12-31Cons.Operating income
Operating income−¥137m2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income−¥68m2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income−¥243m2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥233m2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax−¥70m2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax−¥237m2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)−¥76m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥259m2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥244m2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income−¥76m2022-04-01 → 2022-12-31Cons.Profit loss
Net income−¥244m2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥1.6bnat 2022-12-31Cons.Assets
Total assets¥1.7bnat 2022-03-31Cons.Assets
Total assets¥1.7bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥338mat 2022-12-31Cons.Liabilities
Total liabilities¥337mat 2022-03-31Cons.Liabilities
Net assets / equity¥1.3bnat 2022-12-31Cons.Net assets
Net assets / equity¥1.4bnat 2022-03-31Cons.Net assets
Net assets / equity¥1.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥394mat 2022-12-31Cons.Cash and deposits
Cash and deposits¥508mat 2022-03-31Cons.Cash and deposits
EPS (basic)¥-8.22022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥6.412022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-27.782021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-26.142021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-4.742021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio79.3%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio80.2%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio80.7%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 25
SegmentItemPeriodValue
jpcrp040300-q3r_E00986-000Cosmeticsreportable segmentrevenue2022-04-01 → 2022-12-31¥3m
jpcrp040300-q3r_E00986-000Cosmeticsreportable segmentrevenue external2022-04-01 → 2022-12-31¥3m
jpcrp040300-q3r_E00986-000Cosmeticsreportable segmentsegment profit2022-04-01 → 2022-12-31−¥11m
jpcrp040300-q3r_E00986-000Gene Recombination Silkworm Developmentreportable segmentsegment profit2022-04-01 → 2022-12-31−¥61m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentrevenue2022-04-01 → 2022-12-31¥552m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentrevenue external2022-04-01 → 2022-12-31¥552m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentsegment profit2022-04-01 → 2022-12-31¥92m
—segment totalrevenue2022-04-01 → 2022-12-31¥555m
—segment totalrevenue external2022-04-01 → 2022-12-31¥555m
—segment totalsegment profit2022-04-01 → 2022-12-31¥19m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥3m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥3m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31¥560,000
jpcrp040300-q3r_E00986-000Cosmeticsreportable segmentrevenue2021-04-01 → 2021-12-31¥12m
jpcrp040300-q3r_E00986-000Cosmeticsreportable segmentrevenue external2021-04-01 → 2021-12-31¥12m
jpcrp040300-q3r_E00986-000Cosmeticsreportable segmentsegment profit2021-04-01 → 2021-12-31−¥9m
jpcrp040300-q3r_E00986-000Gene Recombination Silkworm Developmentreportable segmentsegment profit2021-04-01 → 2021-12-31−¥78m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentrevenue2021-04-01 → 2021-12-31¥440m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentrevenue external2021-04-01 → 2021-12-31¥436m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥3m
jpcrp040300-q3r_E00986-000Immunity Relatedreportable segmentsegment profit2021-04-01 → 2021-12-31−¥51m
—segment totalrevenue2021-04-01 → 2021-12-31¥451m
—segment totalrevenue external2021-04-01 → 2021-12-31¥448m
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥3m
—segment totalsegment profit2021-04-01 → 2021-12-31−¥137m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 314
ItemContextValueUnit
Noncurrent liabilitiesPrior1YearInstant108907000JPY
Noncurrent liabilitiesCurrentQuarterInstant105915000JPY
LiabilitiesPrior1YearInstant336990000JPY
LiabilitiesCurrentQuarterInstant338021000JPY
Capital stockPrior1YearInstant3029041000JPY
Capital stockCurrentQuarterInstant3029041000JPY
Capital surplusPrior1YearInstant2061421000JPY
Capital surplusCurrentQuarterInstant2061421000JPY
Retained earningsPrior1YearInstant-3720124000JPY
Retained earningsCurrentQuarterInstant-3796555000JPY
Treasury stockPrior1YearInstant-1990000JPY
Treasury stockCurrentQuarterInstant-1990000JPY
Shareholders equityPrior1YearInstant1368348000JPY
Shareholders equityCurrentQuarterInstant1291917000JPY
Net assetsPrior1YearInstant1368348000JPY
Net assetsCurrentQuarterInstant1291917000JPY
Liabilities and net assetsPrior1YearInstant1705338000JPY
Liabilities and net assetsCurrentQuarterInstant1629938000JPY
Net salesPrior1YTDDuration448082000JPY
Net salesCurrentYTDDuration554909000JPY
Cost of salesPrior1YTDDuration200596000JPY
Cost of salesCurrentYTDDuration190794000JPY
Gross profitPrior1YTDDuration247485000JPY
Gross profitCurrentYTDDuration364114000JPY
Selling general and administrative expensesPrior1YTDDuration384163000JPY
Selling general and administrative expensesCurrentYTDDuration345226000JPY
Operating incomePrior1YTDDuration-136678000JPY
Operating incomeCurrentYTDDuration18887000JPY
Interest income noiPrior1YTDDuration216000JPY
Interest income noiCurrentYTDDuration991000JPY
Foreign exchange gains noiPrior1YTDDuration923000JPY
Foreign exchange gains noiCurrentYTDDuration3363000JPY
Insurance premiums refunded cancellation noiPrior1YTDDuration3623000JPY
Insurance premiums refunded cancellation noiCurrentYTDDuration4820000JPY
Other noiPrior1YTDDuration3285000JPY
Other noiCurrentYTDDuration2209000JPY
Non operating incomePrior1YTDDuration8049000JPY
Non operating incomeCurrentYTDDuration11385000JPY
Interest expenses noePrior1YTDDuration378000JPY
Interest expenses noeCurrentYTDDuration806000JPY
Equity in losses of affiliates noePrior1YTDDuration103868000JPY
Equity in losses of affiliates noeCurrentYTDDuration96557000JPY
Other noePrior1YTDDuration25000JPY
Other noeCurrentYTDDuration546000JPY
Non operating expensesPrior1YTDDuration104272000JPY
Non operating expensesCurrentYTDDuration97910000JPY
Ordinary incomePrior1YTDDuration-232900000JPY
Ordinary incomeCurrentYTDDuration-67637000JPY
Gain on reversal of subscription rights to shares eiPrior1YTDDuration2166000JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass